Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
12.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alvotech - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024
From
Alvotech
Via
GlobeNewswire
ALVO Stock Earnings: Alvotech Reported Results for Q4 2023
March 20, 2024
Alvotech just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 18, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and STADA add to strategic alliance through denosumab partnership
June 11, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Strategic Refinancing Agreement
June 07, 2024
From
Alvotech
Via
GlobeNewswire
2 Generic Drug Makers With Growing Runways
May 31, 2024
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024
From
Alvotech
Via
GlobeNewswire
ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024
May 21, 2024
ALVO stock results show that Alvotech missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024
From
Alvotech
Via
GlobeNewswire
Stocks Hold Steady On Mixed Fed Remarks, First Solar Rallies, Bitcoin Falls Below $70,000: What's Driving Markets Tuesday?
May 21, 2024
It’s a rather quiet session on Tuesday, with major U.S. averages trading around the flatline at midday trading in New York.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
May 13, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
May 02, 2024
From
Alvotech
Via
GlobeNewswire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024
From
Alvotech
Via
GlobeNewswire
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
April 19, 2024
Via
Benzinga
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024
From
Alvotech
Via
GlobeNewswire
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alvotech Announces Increase in Number of Own Shares
March 22, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.